Drug intelligence / Profile preview

PEV7B1

Development stage: Unknown
Lead developer: Pevion Biotech
Modality: Targeted Liposomes → Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

PEV7B1 is a virosome-formulated anti-Candida vaccine candidate developed by Pevion Biotech. It is designed for the prevention of recurrent vulvovaginal candidiasis (RVVC), particularly in pre-menopausal women with a history of this condition. The vaccine leverages virosome technology to present Candida antigens and stimulate an immune response, acting as an immunostimulant. In clinical studies, PEV7B1 was administered via the intramuscular route to evaluate its safety, tolerability, and immunogenicity[5][10]. The primary mechanism involves stimulating the immune system against Candida albicans.

Beyond the preview

Go deeper on PEV7B1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PEV7B1.

Explore the full profile